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How women deal with the results of serum screening for Down
syndrome in the second trimester of pregnancy
Martin J. N. Weinans1*, Annemarie M. G. Huijssoon1, Tjeerd Tymstra2, Mignon C. F. Gerrits1,
Johan R. Beekhuis1 and Albert Mantingh1
1Antenatal Diagnosis Unit, Department of Obstetrics and Gynaecology, University Hospital Groningen, The Netherlands
2Department of Medical Sociology, Faculty of Medical Sciences, University of Groningen, The Netherlands
To gain insight into how pregnant women experience serum screening for Down syndrome, we sent
questionnaires to two groups of relevant subjects in the north of the Netherlands. The questionnaires
addressed the following issues: decision-making process, knowledge and opinions. Questionnaire A was sent
to women of 36 years of age and older (n=99) (group A) who were all 20 to 36 weeks pregnant at that time.
In the Netherlands prenatal diagnosis is routinely available to these women. Questionnaire B was sent to
women of younger than 36 years (n=69) (group B) who had received a screen-positive result and had
subsequently undergone amniocentesis. About half of these women were still pregnant at that time. For
these women, serum screening is only available on the basis of opting-in. The two questionnaires were
largely identical. The response rates to questionnaires A and B were 82% and 91%, respectively. Group A
(women of 36 years and older) considered that second trimester serum screening made a welcome
contribution to the decision-making process about whether to undergo amniocentesis. Moreover, it reduced
the amniocentesis rate considerably. The vast majority said they would apply for serum screening in a
following pregnancy, but favoured the idea of first trimester screening. In group B (women of younger than
36 years), reassurance was the most commonly mentioned reason for undergoing serum screening. Almost
all the women experienced some degree of anxiety when they were informed about the screen-positive result
and 13% continued to be anxious, even after the favourable result of the amniocentesis. The majority of the
respondents would also apply for serum screening in a following pregnancy and were of the opinion that
this screening should be offered to all pregnant women in the Netherlands. Copyright# 2000 John Wiley &
Sons, Ltd.
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INTRODUCTION
Prenatal screening for Down syndrome has been in
practice for the past three decades. Until the mid-
1980s, this screening was only offered to women on the
basis of maternal age and previous history. The
detection rate based on maternal age is about
25–30% for a false-positive rate of 5%, depending on
the age distribution of the population. In 1988, a
screening test for Down syndrome, using a combina-
tion of three biochemical markers (alpha fetoprotein—
AFP, human chorionic gonadotrophin—hCG and
unconjagated oestriol-uE3) and maternal age, pre-
dicted a detection rate of over 60% with a false-
positive rate of 5% (Wald et al., 1988). This is more
than double the detection rate of screening on the basis
of maternal age alone. Since then, various authors
have clearly demonstrated the efficacy of many
different screening programmes (Wald et al., 1992;
Milunsky, 1992; Haddow and Palomaki, 1993). At
present, biochemical screening for Down syndrome is
well established in many countries.
When assessing the performance of maternal serum
screening for Down syndrome in the Netherlands, the
way in which the obstetrical care system is organized
has to be taken into account. It is strongly decen-
tralized and subdivided into first- and second-level
care. Maternal serum screening for Down syndrome
has been available at our centre in the north of the
Netherlands since 1990; it was evaluated by Beekhuis
in 1993. A few thousand serum samples per year are
analysed at our centre; about 60% are sent by
midwives and general practitioners (first-level care),
30% are sent by other hospitals and 10% are from our
own department. Owing to Dutch regulations (The
Population Screening Act of 1992), serum screening is
not offered routinely to all pregnant women. Prenatal
diagnosis does not form part of routine care for
pregnant women younger than 36 years. For these
women serum screening is only available on the basis
of opting-in, whereas women of 36 years of age and
older participate on the basis of opting-out. At our
centre, the result of serum screening in women of 36
years of age and older is given as a numeric value,
whereas in women of younger than 36 years, the result
is given as ‘screen positive’ or ‘screen negative’.
Various studies have focused on women’s experience
of serum screening programmes for Down syndrome,
including their opinions, motives, knowledge and
decision-making processes (Marteau et al., 1992;
Roelofsen et al., 1993; Santalahti et al., 1998; Gekas
et al., 1999; Michie et al., 1999). Nevertheless, certain
questions have remained unanswered. The aim of this
study on women who underwent serum screening was
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to gain insight into the following issues: How much do
they understand? Are they able to recall the informa-
tion they received? What is their actual experience of
this screening? What decisions do they make and what
influences these decisions? What is the impact of the
screening result on the further course of pregnancy?
SUBJECTS AND METHODS
Two semi-structured questionnaires were developed by
interviewing 20 women in their homes about maternal
serum screening for Down syndrome. Questionnaire A
was sent to a sample of pregnant women of 36 years of
age and older. Questionnaire B was sent to women of
younger than 36 years who had undergone second
trimester serum screening and were screen-positive.
We chose 36 years as the cut-off point, because Dutch
regulations restrict routine prenatal diagnosis to
women of 36 years and older.
Questionnaire A
The first questionnaire was sent to 99 women of 36
years of age and older who had undergone maternal
serum screening at around 16 weeks of gestation.
Serum samples were sent by midwives, general
practitioners, other hospitals and some were from
our own department. Risk assessment was done at our
centre. All these women were 20–36 weeks pregnant
when they filled in and returned the questionnaire.
Questionnaire B
The second questionnaire was sent to 69 women
younger than 36 years who had undergone amniocent-
esis at the University Hospital Groningen in the
preceding six months because of a positive serum
screening result for Down syndrome. None of these
amniocenteses showed a chromosomal abnormality.
Of these 44% women were still pregnant when they
filled in and returned the questionnaire, while 56% had
already delivered.
The two questionnaires were largely identical.
Questionnaire B contained more questions about
amniocentesis, whereas questionnaire A focused
more on decision making after the result of serum
screening. We invited the women to write down their
personal experience of prenatal screening at the end of
the questionnaire.
RESULTS
Questionnaire A (women of 36 years and
older)
We received 81 correctly completed questionnaires
(response rate 82%). It appeared that half of the
respondents (52%) had not known about the existence
of serum screening before their present pregnancy.
Table 1 (left column) shows how they found out about
the existence of serum screening. Gynaecologists
played the most important role in this. Other questions
about the information process demonstrated that only
7% of the respondents did not feel wellinformed about
the serum screening, while 24% said that the serum
screening result would tell them whether they were
carrying a child with Down syndrome.
If serum screening had not existed, almost half of
the respondents (47%) would have undergone amnio-
centesis, while the other half would have declined. A
full 50% of the women had decided beforehand at
which specific risk estimate they would have amnio-
centesis; 70% of them chose the risk level based on
their age. Only 12% of the respondents could not recall
the result of their serum screening in numbers. In one
third of the respondents, the risk according to serum
screening was higher than that based solely on their
age. Almost half of the women (49%) had received the
advice from the general practitioner gynaecologist or
midwife, to have or to decline amniocentesis when they
were informed about the serum screening result
(Table 2). Eighty-two per cent of the respondents
stated that the serum screening had helped them to
make a well-founded decision about whether to have
amniocentesis or not.
Twenty-one per cent of the respondents had a
positive serum screening result (Down syndrome risk
of 1 in 250, or higher); 76% decided to have
amniocentesis. None of these amniocenteses showed
a chromosomal abnormality. Seventy-nine per cent of
the respondents had a negative serum screening result;
they all therefore declined amniocentesis. The amnio-
centesis rate for the total group was 16%. In a
subsequent pregnancy almost all the respondents
(93%) said that they would apply for serum screening.
At the end of the questionnaire, we asked whether it
would be considered an advantage to have serum
screening performed in the first trimester of pregnancy.
The vast majority of the respondents (82%) thought
that this would be an advantage. The most commonly
mentioned reasons for preferring first trimester screen-
Table 1—How did you find out about the existence of
serum screening? (You can choose more than one)
i36 years <36 years
General practitioner 12% 17%
Gynaecologist 62% 19%
Midwife 7% 57%
Relatives, acquaintances 15% 19%
Magazines, television 21% 13%
Other 15% 10%
Table 2—Did you receive any advice to have or to decline
amniocentesis from your general practitioner/gynaecologist/
midwife when you were informed about the serum screen-
ing result?
No, I had to make a decision myself 51%
Yes, I was advised to have an amniocentesis 15%
Yes, I was advised to decline an amniocentesis 34%
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ing were the shorter period of uncertainty and the
possibility of first trimester termination of pregnancy
before any fetal movements could be felt.
Questionnaire B (women younger than 36
years)
A total of 63 out of the 69 women responded (response
rate 91%). Table 1 (right column) shows how they had
found out about the existence of serum screening. It
appears that the midwives played an important role.
Only 6% of the women felt that they had not been
wellinformed about the serum screening, whereas 29%
of respondents said that the serum screening result
would tell them whether they were carrying a child
with Down syndrome.
We asked the women what their reasons were for
wanting serum screening. The most commonly men-
tioned reason was reassurance regarding fetal health
(71%), while 10% answered that they would undergo
any prenatal test available. As one woman stated:
‘This kind of screening has different sides. It is there,
you can use it and it is difficult not to use because the
procedure is so simple. But imagine that something is
wrong and you didn’t have this test. During my
previous pregnancies the test was not available,
making things a lot easier because I didn’t have to
decide.’ Almost all the women (92%) experienced
anxiety after receiving the positive result of serum
screening. We asked the women whether it had been
difficult to decide to have amniocentesis. Forty-one
per cent of the respondents had found it difficult to
decide to have amniocentesis, ranging from slightly to
very difficult.
All the women in group B underwent amniocentesis.
The outcome was favourable in all of them. We asked
whether this favourable result had enabled them to feel
more confident about their pregnancy. Thirteen per
cent of them had continued to experience anxiety
despite the normal amniocentesis result. Only 5% of
the repondents regretted undergoing serum screening
and 17% would not apply for serum screening in a
subsequent pregnancy. Forty-three per cent of the
women concluded that pregnancy became a more
enjoyable experience thanks to these forms of prenatal
diagnosis. Only 15% of the respondents disagreed with
the statement that serum screening should be offered
to all pregnant women in the Netherlands, regardless
of their age.
DISCUSSION
The aim of this study was to gain insight into the
user’s opinions about maternal serum screening for
Down syndrome in the Netherlands. Two distinctive
groups of pregnant women were approached: women
of 36 years of age and older (to whom this screening is
routinely offered) and younger women (for whom
serum screening is only available on the basis of
opting-in).
It is well known that serum screening in women of
36 years of age and older has a positive effect on the
amniocentesis rate (and the associated fetal loss) and
that it also facilitates decision making about amnio-
centesis (Haddow et al., 1994). In our study, the most
important reason for amniocentesis was not only a
positive serum screening result (Down syndrome risk
of 1 in 250, or higher) but, in particular, a higher risk
according to serum screening than a risk based solely
on age. On the other hand, all women with a negative
serum screening result decided to decline amniocent-
esis. The amniocenteses rate in our study diminished
from 47% to 16%, a reduction of 66%.
Although the positive effects of serum screening
predominate in the group of women aged 36 years and
older, the negative effects are more pronounced in the
group of younger women with a screen-positive result.
The burden of serum screening is mainly psychosocial
and emotional. Previous studies have shown that
women with a positive serum-screening result experi-
ence anxiety while awaiting the result of subsequent
amniocentesis (Marteau et al., 1992). This was
confirmed in our study. The majority of these
women felt much more confident about their preg-
nancy after hearing the favourable result of amnio-
centesis. Despite a few weeks of distress, the majority
of these women felt positively about serum screening
in retrospect. They were of the opinion that serum
screening should be offered to all pregnant women,
regardless of their age. It is disturbing that in our
study, 13% of women younger than 36 years who had
a positive serum screening result continued to experi-
ence some degree of anxiety despite the normal
amniocentesis result. Although our semi-structured
questionnaire did not allow precise quantification of
anxiety levels, this sustained anxiety is in line with the
study of Marteau et al. (1992).
As we did not send questionnaires to women of
younger than 36 years who had a true negative serum
screening result, we can only speculate about their
opinions. It seems likely that these women will have a
positive attitude towards serum screening, because
reassurance is the most commonly mentioned reason
for having this screening test (Santalahti et al., 1998).
It would also be interesting to obtain information
about the opinions of women with a false negative
serum screening result.
Providing a sufficient level of counselling about
serum screening and possible subsequent amnio-
centesis continues to be a challenging issue. What
information does a woman or couple need in order to
make well-founded decisions? In our study almost all
women felt that they had been well-informed about the
serum screening. Nonetheless, about one quarter of
them supposed that the serum screening result would
tell them whether or not they were carrying a Down
syndrome child. This demonstrates lack of knowledge.
Similar observations have been reported in previous
studies (Goel et al., 1996; Gekas et al., 1999). Accurate
information provided by health professionals could
possibly raise knowledge levels. But, is it possible to
reduce the problem of the anxiety that women
experience when they receive a screen-positive result
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merely by improving the counselling process? We
agree with Santalathi et al. (1998) that this is unlikely
because the reason for participating in serum screening
is not to find out whether they belong to a risk group,
but to obtain reassurance about the health of the fetus.
We do not think that changing the current method of
counselling would make the drawbacks of serum
screening disappear.
The finding of Kornman et al. (1997) that women in
our region favour first trimester screening over second
trimester screening, was confirmed in this study. The
most commonly mentioned reasons for preferring first
trimester screening were the shorter period of uncer-
tainty and the possibility of first trimester termination
of pregnancy before any fetal movements could be felt.
In the Netherlands, the Population Screening Act
prohibits offering routine serum screening to women
of younger than 36 years. We think that this policy is
questionable: Does it show respect for women’s
autonomy? Earlier studies have stressed that the
autonomy principle of the individual should be
considered a basic right, as expressed by women
when asked their opinions about screening (Tymstra
et al., 1991). The majority of the women younger than
36 years in our study (they all had a screen-positive
result) confirmed this by indicating that serum screen-
ing should be offered to all pregnant women in the
Netherlands, regardless of their age. We agree with
them: it is improper to exclude women younger than
36 years from serum screening.
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